Bourla praises Trump as RFK Jr. preps vaccine review; Will CRISPR matter?; Atomwise hires new CEO; and morenews2025-02-22T11:00:17+00:00February 22nd, 2025|Endpoints News|
Updates from Washington; A trio of Big Pharma deals; What do recent share buybacks mean for M&A?; and morenews2025-02-15T11:00:13+00:00February 15th, 2025|Endpoints News|
Q4 earnings updates; Biogen details revised research strategy; RFK Jr. advances out of Senate committee; and morenews2025-02-08T11:00:30+00:00February 8th, 2025|Endpoints News|
RFK Jr. hearings leave key GOP senator “struggling”; Drugmakers report Q4 earnings; Leerink builds healthcare M&A team; and morenews2025-02-01T11:00:55+00:00February 1st, 2025|Endpoints News|
Biogen paring back research efforts; Will Chinese biotechs threaten US dominance?; What the new administration means for pharma ; and morenews2025-01-25T11:00:16+00:00January 25th, 2025|Endpoints News|
JPM’s M&A Monday frenzy; Ozempic selected for IRA negotiations; Pfizer says it’s back on track; and morenews2025-01-18T11:00:23+00:00January 18th, 2025|Endpoints News|
DNA edit leads to apparent cure in infant; CDER director to step down; More biotechs emerge with assets from China; and morenews2025-01-11T11:00:57+00:00January 11th, 2025|Endpoints News|
Neumora fails Ph3 depression study; Our review of 2024 megarounds; Pfizer cuts Sangamo pact; and morenews2025-01-04T11:00:45+00:00January 4th, 2025|Endpoints News|
2024’s biopharma winners and losers; CagriSema falls short; Merck swings China GLP-1 deal; and morenews2024-12-21T11:00:31+00:00December 21st, 2024|Endpoints News|
The Endpoints 100 is back; Inside Isomorphic Labs; FDA adcomm discusses severe RSV cases; and morenews2024-12-14T11:00:05+00:00December 14th, 2024|Endpoints News|
